<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055887</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000271438</org_study_id>
    <secondary_id>ALLOS-RSR13RT-013ELITE</secondary_id>
    <nct_id>NCT00055887</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Drugs such as efaproxiral may make the tumor cells more sensitive to radiation therapy. It is&#xD;
      not yet known if chemotherapy combined with radiation therapy is more effective with or&#xD;
      without efaproxiral in treating non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy combined&#xD;
      with radiation therapy with or without efaproxiral in treating patients who have stage III&#xD;
      non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival of patients with stage IIIA or IIIB non-small cell lung&#xD;
           cancer treated with induction chemotherapy followed by radiotherapy with or without&#xD;
           efaproxiral.&#xD;
&#xD;
        -  Compare time to progression, response rate, and pattern of failure of patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Determine the safety of efaproxiral in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of efaproxiral in these patients.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to chemotherapy regimen, Karnofsky performance status (70-80% vs 90-100%), and&#xD;
      disease stage (IIIA vs IIIB).&#xD;
&#xD;
        -  Induction therapy phase: Patients receive 1 of the following induction chemotherapy&#xD;
           regimens:&#xD;
&#xD;
             -  Paclitaxel and carboplatin: Patients receive paclitaxel IV and carboplatin IV on&#xD;
                day 1. Treatment repeats every 21 days for a total of 2 courses.&#xD;
&#xD;
             -  Cisplatin and gemcitabine: Patients receive cisplatin IV on day 2 and gemcitabine&#xD;
                IV on days 1, 8, and 15. Treatment repeats every 28 days for a total of 2 courses.&#xD;
&#xD;
             -  Cisplatin and vinorelbine: Patients receive cisplatin IV on day 1 and vinorelbine&#xD;
                IV on days 1, 8, and either 15 or 22. Treatment repeats every 28 days for a total&#xD;
                of 2 courses.&#xD;
&#xD;
        -  Randomized phase: Within 42 days after completion of chemotherapy, patients are&#xD;
           randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive efaproxiral IV over 30-45 minutes with supplemental oxygen&#xD;
                and then undergo concurrent radiotherapy 5 days a week for 7 weeks.&#xD;
&#xD;
             -  Arm II: Patients receive supplemental oxygen and undergo radiotherapy as in arm I.&#xD;
&#xD;
      Quality of life is assessed at baseline, on days 1 and 16 of radiotherapy, monthly for 3&#xD;
      months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      Patients are followed monthly for 3 months, every 3 months for 2 years, every 6 months for 3&#xD;
      years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 659 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never started. No patients were enrolled.&#xD;
  </why_stopped>
  <start_date>November 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efaproxiral</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced, unresectable non-small&#xD;
             cell lung cancer of 1 of the following subtypes:&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Large cell carcinoma&#xD;
&#xD;
               -  Poorly differentiated carcinoma&#xD;
&#xD;
          -  Stage IIIA or IIIB&#xD;
&#xD;
               -  T1 or T2, N2&#xD;
&#xD;
               -  T3, N1 or N2&#xD;
&#xD;
               -  T4, any N&#xD;
&#xD;
               -  Any T, N3&#xD;
&#xD;
          -  Histological or cytological confirmation of at least 1 positive lymph node required if&#xD;
             the largest mediastinal node that is the basis of stage III disease is less than 2.0&#xD;
             cm in diameter&#xD;
&#xD;
          -  Clinically or radiologically measurable disease of at least 2.0 cm&#xD;
&#xD;
          -  Partially resected stage IIIB disease allowed provided a measurable lesion remains&#xD;
&#xD;
          -  No pleural effusion that is bloody, cytologically positive, or re-accumulated after&#xD;
             thoracentesis&#xD;
&#xD;
          -  No metastatic disease by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically active congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No severe arrhythmia by ECG&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FVC and FEV_1 at least 50% of normal&#xD;
&#xD;
          -  Resting oxygen saturation by pulse oximetry (SpO_2) at least 90% on room air&#xD;
&#xD;
          -  Exercise SpO_2 at least 90% on room air&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use effective contraception during and for 30 days after&#xD;
             study therapy&#xD;
&#xD;
          -  Male patients must use effective contraception during and for 90 days after study&#xD;
             therapy&#xD;
&#xD;
          -  No loss of more than 10% of body weight within the past 3 months&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No significantly altered mental status or dementia that would preclude giving informed&#xD;
             consent&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 28 days since prior biologic therapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors (randomized phase only)&#xD;
&#xD;
          -  No biologic therapy during and for 1 month after study therapy&#xD;
&#xD;
          -  No immune response modifiers during and for 1 month after study therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No hormonal therapy during and for 1 month after study therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior thoracic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior total surgical resection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 28 days since prior investigational drugs or devices&#xD;
&#xD;
          -  No prior efaproxiral&#xD;
&#xD;
          -  No other cytotoxic therapy during and for 1 month after study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hak Choy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Cancer Center</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Lexington Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willis - Knighton Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103-3951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Everett Medical Center - Pacific Campus</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiffler Cancer Center</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Hopital Fleurimont</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre- Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Efaproxiral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

